Myositis
56
10
15
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.4%
3 terminated out of 56 trials
88.0%
+1.4% vs benchmark
5%
3 trials in Phase 3/4
23%
5 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 22 completed trials
Clinical Trials (56)
Environmental Risk Factors for Myositis in Military Personnel
Environmental Risk Factors for the Anti-synthetase Syndrome
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
A Study to Test CRT-402 in Refractory Autoimmune Disease
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies
Muscle Imaging Project Using ANatomopathology and Full Field Optical Coherence Tomography
Muscle Health Measurements Using Electrical Impedance Myography
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Pregnancy and Medically Assisted Conception in Rare Diseases
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Add-on Intravenous Immunoglobulins in Early Myositis
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis